摘要
在联合化疗方案基础上加用重组人粒细胞集落刺激因子（G－CSF）和重组白细胞介素－2（IL－2）治疗AML22例，并以单用联合化疗方案的18例为对照组，进行疗效随访观察。结果：治疗组完全缓解率81．8％，对照组72．2％（P＞0．05）。到1996年10月，治疗组缓解或4～48个月，中数缓解期19．6个月，生存期6～51个月，中数生存期23个月；对照组中数缓解期13．5个月（4～32个月），中数生存期14．6个月（5～36个月）。治疗组缓解期和生存期优于对照组（P＜0．05）。
To explore more effective modality for adult acute myelogenous leukemia (AML) Twenty-two patients were treated with combination chemotherapy protocol plus G-CSF and IL-2 form Jun. 1992 to Jun. 1996, and eighteen patients treated with combination chemotherapy protocol alone (control group). The complete re mission (CR) rate was 81. 8% for G-CSF and IL-2 group, and 72.2% for control group (P>0.05). Up to Oct. 1996,the median CR duration was 19.6 months (4 to 48 months) and the median survival time was 23 months (6 to 51 months) for G CSF and IL-2 group. The median CR duration was 13. 5 months (4 to 32 months) and median survival time was 14. 6 months (5 to 36 months) for contol group. The median CR duration and the median surrival time was significantly higher in G-CSF and IL-2 group than that in control group (P < 0.05). The combination chemotherapy protocol plus G-CSF and IL-2 might prolong AML patients CR dura tion and survival time, shorten the recovery period of decreased granulocytes and enhance the control of infection with less side effects and more safety. We conclud ed that the combination chemoterapy protocol plus G-CSF and IL-2 was a safer and more effective therapy for AMI, ljatlents.
出处
《临床血液学杂志》
CAS
1998年第1期10-12,共3页
Journal of Clinical Hematology
关键词
白血病
髓细胞性
联合化疗
IL-2
G-CSF
Acute myelogenous leukemia Combination chemotherapy Granulocyte colony stimulating factor Interleukin-2
